abstract |
The present invention relates to thymosin β4 (TB4) fusion polypeptides and in particular to TB4 fusion polypeptides having a longer serum half-life than wild-type TB4. The present invention also relates to TB4 fusion polypeptides for use as a medicament, and to methods of treatment using said TB4 fusion polypeptides. In particular, the present invention provides TB4 fusion polypeptides for use in methods of prevention or treatment of myocardial infarction, muscle wasting conditions and diseases and diabetic nephropathy. |